Denmark-based major life science investor Novo Holdings, has entered into an agreement whereby it will acquire New York listed CDMO Catalent in an all-cash transaction that values Catalent at US$16.5bn…
US: Novo Holdings agrees to acquire Catalent for US$16.5bn
…
…






